Corona Remedies Intrinsic Value
Corona Remedies (CORONA) median intrinsic value is ₹635.82 from 10 valuation models (range ₹424–₹1060), vs current price ₹2119.40 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse CORONA shareholding pattern to track promoter, FII and institutional holdings.
CORONA Valuation Methods Summary — DCF, Graham Number & P/E
Corona Remedies intrinsic value across 10 models vs current price ₹2119.40 — upside/downside and value range per method. For current market price and key ratios, visit Corona Remedies share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹652.08 | ₹521.66 - ₹782.50 | -69.2% | EPS: ₹29.64, Sector P/E: 22x |
| Book Value Method | asset | ₹423.88 | ₹381.49 - ₹466.27 | -80.0% | Book Value/Share: ₹122.46, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹635.82 | ₹572.24 - ₹699.40 | -70.0% | Revenue/Share: ₹234.75, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹847.76 | ₹762.98 - ₹932.54 | -60.0% | EBITDA: ₹264.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹847.76 | ₹678.21 - ₹1017.31 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹635.82 | ₹572.24 - ₹699.40 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹635.82 | ₹572.24 - ₹699.40 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1059.70 | ₹953.73 - ₹1165.67 | -50.0% | ROE: 24.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹635.82 | ₹572.24 - ₹699.40 | -70.0% | EPS: ₹29.64, BVPS: ₹122.46 |
| Dividend Yield Method | dividend | ₹635.82 | ₹572.24 - ₹699.40 | -70.0% | DPS: ₹10.00, Target Yield: 2.5% |
CORONA Intrinsic Value vs Market Price — All Valuation Models
Corona Remedies fair value range ₹424–₹1060 vs current market price ₹2119.40 across 10 valuation models. Read CORONA dividend growth for the complete payout history and dividend yield track record.
CORONA Intrinsic Value Analysis — Undervalued or Overvalued?
Corona Remedies median intrinsic value ₹635.82, current price ₹2119.40 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of CORONA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Corona Remedies (CORONA) is ₹635.82 (median value). With the current market price of ₹2119.40, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹423.88 to ₹1059.70, indicating ₹423.88 - ₹1059.70.
Is CORONA undervalued or overvalued?
Based on our multi-method analysis, Corona Remedies (CORONA) appears to be trading above calculated value by approximately 70.0%.
CORONA Financial Health — Key Ratios vs Industry Benchmarks
Corona Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.59 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 24.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.19x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
CORONA Cash Flow Quality — Operating & Free Cash Flow
Corona Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹230 Cr | ₹102 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹191 Cr | ₹149 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹157 Cr | ₹24 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹103 Cr | ₹78 Cr | Positive Free Cash Flow | 8/10 |